F Dx Advisors, Inc. Neurocrine Biosciences Inc Transaction History

F Dx Advisors, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$106.07 - $132.76 $213,306 - $266,980	2,011 New	2,011 $265,000
Q4 2022 Feb 09, 2023	SELL	$106.72 - $127.06 $35,110 - $41,802	-329 Reduced 9.43%	3,159 $377,000
Q3 2022 Nov 10, 2022	SELL	$92.03 - $107.81 $142,554 - $166,997	-1,549 Reduced 30.75%	3,488 $370,000
Q2 2022 Aug 03, 2022	SELL	$75.79 - $100.07 $43,655 - $57,640	-576 Reduced 10.26%	5,037 $491,000
Q1 2022 May 03, 2022	BUY	$72.45 - $94.81 $197,716 - $258,736	2,729 Added 94.63%	5,613 $526,000
Q4 2021 Feb 01, 2022	SELL	$79.65 - $106.22 $173,557 - $231,453	-2,179 Reduced 43.04%	2,884 $246,000
Q3 2021 Oct 08, 2021	BUY	$86.18 - $99.03 $53,517 - $61,497	621 Added 13.98%	5,063 $486,000
Q2 2021 Aug 05, 2021	BUY	$89.43 - $102.27 $14,934 - $17,079	167 Added 3.91%	4,442 $432,000
Q1 2021 Apr 14, 2021	BUY	$87.57 - $119.4 $337,932 - $460,764	3,859 Added 927.64%	4,275 $416,000
Q1 2021 Apr 13, 2021	SELL	$87.57 - $119.4 $198,871 - $271,157	-2,271 Reduced 84.52%	416 $40,000
Q4 2020 Feb 08, 2021	BUY	$86.91 - $108.33 $27,115 - $33,798	312 Added 13.14%	2,687 $258,000
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $1.26 Million - $1.76 Million	-13,054 Reduced 84.61%	2,375 $228,000
Q1 2020 May 13, 2020	BUY	$75.11 - $113.76 $1.16 Million - $1.76 Million	15,429 New	15,429 $42,000

624

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.